eli lilly cease and desist letter tirzepatide The legal battle continues – Novo now seeks a temporary ban on Lilly's advertisements Eli Lilly (LLY) Demands Doctors

Originally developed to treat HIV-associated lipodystrophy, it has shown impressive results in metabolic syndrome and general abdominal obesity

This process, called delayed gastric emptying, helps people feel full longer and eat less

This is a decision to make with your oncology team rather than on your own

FDA update: Wadden article: Tom Wadden Robert Kushner, MD #Obesity #ObesityCare #GLP1 #Tirzepatide #Semaglutide #EvidenceBasedMedicine #PatientSafety #TheObesitySociety This FDA label update is a welcome clarification, particularly for clinicians navigating the complexities of obesity management and mental health comorbidity

That is not a criticism